- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT03105349
A Clinical Trial of 16 Weeks of Duration to Evaluate Retreatment With Elbasvir/Grazoprevir Plus Sofosbuvir and Ribavirin in Patients With Chronic Hepatitis C Genotypes 1,4 Who Have Failed to Treat With a Regime Based on an Inhibitor of the NS5A (C-RESCUE)
7 juni 2018 uppdaterad av: Fundacion SEIMC-GESIDA
A Phase III, Open Label, Multicentric Clinical Trial of a Single Arm of 16 Weeks of Duration to Evaluate Retreatment With Elbasvir/Grazoprevir Plus Sofosbuvir and Ribavirin in Patients With Chronic Hepatitis C Genotype 1,4 Who Have Failed to Treat With a Regime Based on an Inhibitor of the NS5A
This is a phase 4 clinical trial to treat patients who have failed to treat with regimen based on an inhibitor of the NS5A
Studieöversikt
Status
Indragen
Betingelser
Intervention / Behandling
Detaljerad beskrivning
The duration of the treatment will be 16 weeks and then will be a security perid with 2 visits (Week 12 post treatment and week 24 post treatment) The study in an open label study with a single arm .
Studietyp
Interventionell
Fas
- Fas 4
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
-
Madrid, Spanien, 28031
- Hospital Infanta Leonor
-
Madrid, Spanien, 28007
- Hospital Univ. Gregorio Marañon
-
Madrid, Spanien, 28041
- Hospita 12 de octubre
-
Madrid, Spanien, 28046
- Hospital Univ. La Paz
-
-
Madri
-
Madrid, Madri, Spanien, 28046
- Hospital Univ. La Paz
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
- Barn
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Allt
Beskrivning
Inclusion Criteria:
- Adults with chronic HCV genotype 1, 4 infection with or without HIV infection aged 18 years or above
- HCV RNA plasma concentration of at least 1000 IU / mL
- Subjects previously treated with NS5A-based regimens for at least 8 weeks.
- Patients with HCV relapse after receiving a complete treatment with NS5A-based AAD regimen for at least 8 weeks and becoming undetectable at the end of treatment. Relapse is defined as a confirmed HCV RNA detectable upon completion of therapy of A5 based on NS5A against HCV.
- Subjects with compensated hepatic cirrhosis (Child A) could be included.
For patients with HIV coinfection:
- Be infected with HIV-1, documented by any rapid HIV test with the corresponding license and confirmed by a Western blot or second antibody test using a method other than the initial rapid HIV and / or I / CIA method or by HIV-1 p24 antigen or viral load of HIV-1 RNA plasma.
- Be on stable HIV antiretroviral therapy (ART) for at least 4 weeks prior to entry into the study using a dual ITN backbone of tenofovir or abacavir and emtricitabine or lamivudine PLUS raltegravir or dolutegravir or rilpivirine (with CD4 + T cell count> 100 cells / mm 3 and undetectable HIV-1 RNA at baseline. Results from prior analysis will be accepted within 24 weeks prior to study entry).
Exclusion Criteria:
- Subjects with hepatitis other than C or steatosis.
- Subjects previously treated less than 8 weeks with regimens based on NS5A.
- Evidence of previous hepatocellular carcinoma although it has criteria of cure
- Subjects with past or current decompensated liver disease; Only decompensated patients who have received a liver transplant and have not decompensated after transplantation will be included.
- Subjects suspected of clinical or genotypic reinfection of HCV.
- Subject with HCV response regrowth while receiving NS5A-based ADA therapy against HCV. Said regrowth is defined as a confirmation of detectable HCV RNA after achieving undetectable HCV RNA during NS5A-based AADs against HCV.
- Recent history of drug or alcohol abuse.
Important comorbidities.
- Pregnant, lactating or non-lactating women Contraceptives, if they are women of childbearing age. Women of childbearing age are defined as those women who have not undergone permanent infertility procedures or who have been amenorrheic for less than 12 months.
- Subjects with a glomerular filtration rate of less than 30 ml / min.
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Single arm
16 weeks treatment with elbasvir/grazoprevir plus sofosbuvir and ribavirina
|
16 weeks treatment
Andra namn:
16 weeks treatment
16 weeks treatment
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
The rate of patients achieved SVR12
Tidsram: Week 12 post treatment
|
Week 12 post treatment
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
The proportion of subjects infected with HCV genotype 1a with reference VARs NS5A / NS3 who achieved RVS12.
Tidsram: Week 12 post treatment
|
To analyze the impact of VARs NS5A/NS3 on RVS12
|
Week 12 post treatment
|
The proportion of subjects infected with HCV genotype 1b with reference VARs NS5A / NS3 who achieved RVS12.
Tidsram: Week 12 post treatment
|
Analyze the impact of VARs NS5A/NS3 on RVS12
|
Week 12 post treatment
|
The proportion of subjects infected with HCV genotype 4 with reference VARs NS5A /NS3 who achieved RVS12.
Tidsram: Week 12 post treatment
|
Analyze the impact of VARs NS5A/NS3 on RVS12
|
Week 12 post treatment
|
The proportion of subjects infected with HCV genotypes 1.4 with reference VARs NS5A /NS3 who achieved RVS24.
Tidsram: Week 24 post treatment
|
Analyze the impact of VARs NS5A/NS3 on RVS24
|
Week 24 post treatment
|
The occurrence of Viral resistance variants (VARs) to NS5A or elbasvir, to NS3 or grazoprevir and to NS5B or SOF in patients who did not reach SVR12 after 16 weeks of re-treatment
Tidsram: Week 16
|
the occurrence of resistance in patients who did not reach SVR12 after 16 weeks of re-treatment
|
Week 16
|
The occurrence of resistance variants (VARs) viral to NS5A or elbasvir, to NS3 or grazoprevir, and to NS5B or SOF in HIV patients included
Tidsram: Week 12 post treatment
|
The impact of VARs NS5A/NS3 on RVS12 The proportion of subjects developing HIV-1 virological failure (HIV RNA> 200 Copies / mL), confirmed in 2 consecutive tests with at least 2 weeks between them. |
Week 12 post treatment
|
The proportion of subjects developing HIV-1 virological failure (HIV RNA> 200 Copies / mL), confirmed in 2 consecutive tests with at least 2 weeks between them
Tidsram: Week 4, week 8, week 12 and week 16
|
the impact of treatment with EL / BRA plus SOFT and ribavirin in HIV-1 subjects
|
Week 4, week 8, week 12 and week 16
|
The proportion of subjects experiencing adverse events of high laboratory values who report as ECI at any time during the study period.
Tidsram: Week 4, week 8, week 12, week 16, week 12 post-treatment and week 24 post-treatment
|
Adverse events
|
Week 4, week 8, week 12, week 16, week 12 post-treatment and week 24 post-treatment
|
The proportion of subjects with at least one adverse experience
Tidsram: Week 4, week 8, week 12, week 16, week 12 post-treatment and week 24 post-treatment
|
Adverse events
|
Week 4, week 8, week 12, week 16, week 12 post-treatment and week 24 post-treatment
|
The proportion of subjects with an adverse experience related to medication
Tidsram: Week 4, week 8, week 12, week 16, week 12 post-treatment and week 24 post-treatment
|
Adverse events
|
Week 4, week 8, week 12, week 16, week 12 post-treatment and week 24 post-treatment
|
The proportion of subjects with a severe adverse experience
Tidsram: Week 4, week 8, week 12, week 16, week 12 post-treatment and week 24 post-treatment
|
Adverse events
|
Week 4, week 8, week 12, week 16, week 12 post-treatment and week 24 post-treatment
|
The proportion of subjects with a serious adverse experience related to medication
Tidsram: Week 4, week 8, week 12, week 16, week 12 post-treatment and week 24 post-treatment
|
Adverse events
|
Week 4, week 8, week 12, week 16, week 12 post-treatment and week 24 post-treatment
|
The proportion of subjects with an adverse experience leading to disruption
Tidsram: Week 4, week 8, week 12, week 16, week 12 post-treatment and week 24 post-treatment
|
Adverse events
|
Week 4, week 8, week 12, week 16, week 12 post-treatment and week 24 post-treatment
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Förväntat)
1 juli 2017
Primärt slutförande (Förväntat)
1 december 2017
Avslutad studie (Förväntat)
1 februari 2018
Studieregistreringsdatum
Först inskickad
16 mars 2017
Först inskickad som uppfyllde QC-kriterierna
6 april 2017
Första postat (Faktisk)
7 april 2017
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
8 juni 2018
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
7 juni 2018
Senast verifierad
1 juni 2018
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Matsmältningssystemets sjukdomar
- RNA-virusinfektioner
- Virussjukdomar
- Infektioner
- Blodburna infektioner
- Smittsamma sjukdomar
- Leversjukdomar
- Flaviviridae-infektioner
- Hepatit, Viral, Human
- Hepatit, kronisk
- Hepatit
- Hepatit C
- Hepatit C, kronisk
- Molekylära mekanismer för farmakologisk verkan
- Anti-infektionsmedel
- Antivirala medel
- Antimetaboliter
- Sofosbuvir
- Ribavirin
- Grazoprevir
- Elbasvir-grazoprevir läkemedelskombination
Andra studie-ID-nummer
- GESIDA 9516
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Nej
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Nej
Studerar en amerikansk FDA-reglerad produktprodukt
Nej
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på HCV
-
Ascletis Pharmaceuticals Co., Ltd.Avslutad
-
Ain Shams UniversityAvslutad
-
PfizerAvslutad
-
Bristol-Myers SquibbAvslutadHCV (genotyp 1)Förenta staterna, Puerto Rico
-
Valme University HospitalBoehringer IngelheimOkändHCV-infektion. | HCV viral belastning.Spanien
-
Johns Hopkins UniversityNational Institute of Allergy and Infectious Diseases (NIAID)Rekrytering
-
Tibotec Pharmaceuticals, IrelandAvslutad
-
Kirby InstituteAustralasian Society for HIV Viral Hepatitis and Sexual Health Medicine... och andra samarbetspartnersRekrytering
-
National Institutes of Health Clinical Center (CC)Bristol-Myers Squibb; National Institute of Allergy and Infectious Diseases...Avslutad
-
Assiut UniversityOkänd
Kliniska prövningar på elbasvir/grazoprevir
-
National Cheng-Kung University HospitalMerck Sharp & Dohme LLCAvslutadPotentiering av läkemedelsinteraktionTaiwan
-
Institut de Médecine et d'Epidémiologie Appliquée...Merck Sharp & Dohme LLC; Institut National de la Santé Et de la Recherche...Avslutad
-
University Hospital, ToulouseMSD FranceAvslutadKroniska njursjukdomar | Hepatit CFrankrike
-
Erasmus Medical CenterAvslutadHepatit C | Humant immunbristvirus | Akut hepatit CNederländerna, Belgien
-
San Francisco Veterans Affairs Medical CenterMerck Sharp & Dohme LLCOkänd
-
Merck Sharp & Dohme LLCAvslutad
-
King Fahad Medical CityAvslutadHepatit C, kroniskSaudiarabien
-
Merck Sharp & Dohme LLCAvslutad
-
King Faisal Specialist Hospital & Research CenterMerck Sharp & Dohme LLCOkänd
-
Oregon Health and Science UniversityAvslutadMissbruk, intravenöst | Hepatit C | SubstansmissbrukFörenta staterna